By asking whether similar mechanisms could also intervene in cancers derived from other epithelia, we demonstrated that pro-resolving pathways could also exert anti-angiogenic activity in a lung cancer model; however, in this context, the innate immune receptor that controls SPM production is the Toll-like receptor 7 (TLR7) [52]. The gene discussed is TLR7; the disease is lung carcinoma.